Hematologic Malignancies
News
FDA approves epcoritamab for r/r DLBCL
Epcoritamab for adults with relapsed/refractory diffuse large B-cell lymphoma has been approved by the FDA.
News
What’s Causing Cancers at Air Force Bases?
Conference Coverage
Frontline CLL treatment: Avoiding adverse events
Single-agent frontline therapy helps patients with CLL live longer, but those at high risk of relapse may benefit from multiagent treatment.
Conference Coverage
Relapsed CLL: New approaches prolong survival
Venetoclax, with a second-generation generation Bruton’s tyrosine kinase inhibitor, can lead patients with relapsed CLL back to remission.
News
Price of CLL Rx rises, despite competition
The cost of ibrutinib keeps going up, in spite of newer treatment options.
News
MRD: Powerful metric for CLL research
New study showed how leukemia specialists can harness measurable residual disease to gauge the efficacy of novel treatment options.
News
B-cell cancers: Sparse insight into preventing infections
Doctors treating CLL and other B-cell cancers are blindsided by a lack of research into acquired hypogammaglobulinemia prophylactics.
News
CLL and surgery are more compatible than ever
As patients fare better with targeted therapy, physicians say they can tolerate more procedures.
News
CLL treatment: More infections among real-world patients
Among real-world blood cancer patients treated with three drugs, study finds higher infection rates than in clinical trials.
News
Maternal infection in pregnancy ups risk for childhood leukemia?
Maternal infections during pregnancy may be associated with chromosomal and immunologic alterations in the fetus, the authors of the study...